PharmaLive » Therapeutics

Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up ...

https://www.pharmalive.com/biogen-cost-cuts-drive-profit-beat-alzheimers-drug-sales-jump/

Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates. The post Roche tri...

https://www.pharmalive.com/roche-trims-four-early-assets-as-q1-sales-slip-6-percent-on-currency-covid-headwinds/

The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatr...

https://www.pharmalive.com/day-ones-ojemda-gets-fda-accelerated-approval-for-pediatric-brain-tumor/

The company has resumed dismissing employees as part of an ongoing workforce reduction of about 10%. The post BMS initiates first round of layoffs in New Jersey appeared first on PharmaLive .

https://www.pharmalive.com/bms-initiates-first-round-of-layoffs-in-new-jersey/

The European Commission launched a probe into China's public procurement of medical devices, the latest in a series of moves that ratchet up trade tensions ahead of President Xi Jinping's visit t...

https://www.pharmalive.com/eu-launches-investigation-into-chinese-medical-device-market/

Overweight or obese patients with heart conditions insured under the U.S. Medicare program could be eligible for coverage of Novo Nordisk's weight-loss drug Wegovy, a study published by Kaiser F...

https://www.pharmalive.com/about-3-6-mln-medicare-beneficiaries-could-be-eligible-for-wegovy-coverage-study-shows/

Novartis has been hit with a lawsuit by people with autism and their mothers alleging the drugmaker illegally promoted an asthma drug for treatment of preterm labor despite knowing it was ineffec...

https://www.pharmalive.com/novartis-accused-of-promoting-asthma-drug-for-preterm-labor-despite-brain-risk/

Yesterday the agency denied approval for Abeona Therapeutics’ investigational gene-corrected cell therapy prademagene zamikeracel (pz-cel) for the treatment of recessive dystrophic epidermoly...

https://www.pharmalive.com/fda-rejects-abeonas-epidermolysis-bullosa-cell-therapy-asks-for-cmc-data/

CEO Hervé Hoppenot said on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market ...

https://www.pharmalive.com/incyte-inks-750m-deal-to-buy-escient-and-skin-disease-drug-candidates/

Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved durable platelet response in patients with chronic immune thrombocytopeni...

https://www.pharmalive.com/sanofis-3-7b-principia-buy-starts-to-pay-off-with-phase-iii-rilzabrutinib-win/